Last updated: 2026-09-07 11:43:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Protagonist Therapeutics, Inc. (PTGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $145,75, with a market capitalization of $9,43B and a P/E ratio of 113,73. Over the past 52 weeks, its price has ranged from $54,50 to $160,81. This page covers its latest market performance, valuation, price trends and company information.
$9,43B | |
$146,47 | |
$160,81 | |
$4,47 | |
$148,80 | |
328,41K | |
668,90K | |
113,73 | |
$160,81 | |
$54,50 | |
-- | |
-- |
Protagonist Therapeutics, Inc. (PTGX) last closed at $148,80 as of 2026-09-04 23:31:00, unchanged from the previous close of $148,80.
During the latest regular trading session, PTGX traded between $4,47 and $160,81, with a volume of 328,41K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Protagonist Therapeutics, Inc. (PTGX) moved from $149,50 to $145,75, representing a decline of 2,51% ($3,75).
The stock traded between $141,95 and $152,61 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 485,93 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 85,8%
PTGX is currently trading at $145,75, placing it 85,8% of the way from its 52-week low of $54,50 to its 52-week high of $160,81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 141 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Protagonist Therapeutics, Inc. (PTGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.